ClinicalTrials.gg
TerminatedNCT00766181Updated May 25, 2010

Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department

An observational study in Intravenous Placement Procedure, sponsored by Anesiva, Inc.. Terminated. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-05-25.

Sponsored by Anesiva, Inc. · Observational

How we know

Why this study was terminated
Product withdrawn from distribution

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine the satisfaction among parents and nurses of pediatric patients with IV catheter placement in the Emergency Department.

Read the detailed description

The objectives of this study are to evaluate whether the proportion of parents satisfied with their child's IV placement procedure is higher after the introduction of Zingo compared to standard of care and to evaluate changes in nursing staff satisfaction with performing IV placement procedures after using Zingo prior to IV placement compared to standard of care.

02

Conditions studied

  • Intravenous Placement Procedure

Keywords

  • IV placement; Parent satisfaction level
03

In context

Lead sponsor

Anesiva, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients in Emergency Department requiring peripheral IV catheter placement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PHASE A: Parent of a pediatric patient from the age of 3 to 18 years of age who requires a peripheral IV placement in the Emergency Department
  • Parent must be able to read and understand English and provide written
  • Parent must be present during the IV placement
  • PHASE B: Parent did not participate in Phase A
  • Nurse has completed Zingo TM in-service training prior to participation
  • Zingo is used prior to performing the IV placement procedure

Exclusion criteria

Exclusion Criteria:

  • Parent of patient with a serious unstable medical or psychological condition that would compromise participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)

Groups and cohorts

  • 1: Lifestyle

    Observatonal

  • 2: Lifestyle

    Observational

    Behavioral: Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system

Interventions

  • BehavioralZingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system

    0.5 mg lidocaine hydrochloride

06

What researchers measure

Primary outcomes

  1. Parent's satisfaction with IV placement procedure

    Time frame: 18 weeks

Secondary outcomes

  1. Nurse'e satisfaction with performing IV placement

    Time frame: 18 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2008
First posted
Oct 3, 2008
Start
Oct 2008
Primary completionEst.
Feb 2009
CompletionEst.
Apr 2009
Last update
May 25, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00766181
Lead sponsor
Anesiva, Inc.
Collaborators
Covance
First posted
Oct 3, 2008
Start date
Oct 2008
Primary completion
Feb 2009 (estimated)
Completion
Apr 2009 (estimated)
Last update
May 25, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion